ArticleCureus2024
Four Cases of Single-Fraction Stereotactic Body Radiation Therapy for Prostate Cancer.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypofractionated radiotherapy for prostate cancer has been reported to date. Here, we report on four patients with prostate cancer who were treated with single-fraction stereotactic body radiation therapy. It was conducted with reference to some previous clinical trials. The median age of the patients was 76.5 years (range: 72-89 years). All except one patient with low-risk prostate cancer received androgen deprivation therapy (ADT) before irradiation. All patients received a dose of 24 Gy in one fraction using X-ray photon beams when prostate-specific antigen (PSA) fell to low levels due to ADT. After irradiation, all patients had a gradual decline in PSA, and so far none has had a PSA recurrence. Although Grade 1-2 adverse events occurred in all cases, none of the patients showed adverse events of Grade 3 or over during the observation period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.